Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Si-Da Ruan"'
Publikováno v:
Pharmaceutical Fronts, Vol 03, Iss 01, Pp e23-e29 (2021)
Abstract Parathyroid hormone (PTH)1–34 is an effective peptide drug for osteoporosis therapy. However, the half-life of PTH1–34 in vivo is short, leading to the need for frequent injections of this drug during its treatment. To prolong the half-l
Externí odkaz:
https://doaj.org/article/1355a70fbb414001a4dfeda5a840f6ae
Publikováno v:
Pharmaceutical Fronts, Vol 02, Iss 04, Pp e160-e167 (2020)
Adalimumab, a full-length monoclonal antibody, is widely used as an anti-tumor necrosis factor-α (anti-TNF-α) agent. In this article, we aimed to prolong the in vivo half-life of adalimumab antigen-binding fragment (Fab) through Sortase A (SrtA)-me
Externí odkaz:
https://doaj.org/article/5383e01842be40e1b986e7b6273dd37b
Publikováno v:
Pharmaceutical Fronts, Vol 02, Iss 04, Pp e160-e167 (2020)
Adalimumab, a full-length monoclonal antibody, is widely used as an anti-tumor necrosis factor-α (anti-TNF-α) agent. In this article, we aimed to prolong the in vivo half-life of adalimumab antigen-binding fragment (Fab) through Sortase A (SrtA)-me
Publikováno v:
Pharmaceutical Fronts, Vol 03, Iss 01, Pp e23-e29 (2021)
Parathyroid hormone (PTH)1–34 is an effective peptide drug for osteoporosis therapy. However, the half-life of PTH1–34 in vivo is short, leading to the need for frequent injections of this drug during its treatment. To prolong the half-life of PT